71% — Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report No Results Phase 3 results in SAM-002
Leader: No Results at 71% · Kalshi 71% · 5 contracts · $560 volume · medium confidence
Updated 2026-06-26 14:00:54 UTC

Tracks the leading outcome in a winner-take-all prediction market set with 5 outcomes.

Why this matters:
This market reflects a 65% probability that Samson Clinical Operations' sublingual minoxidil treatment for male hair loss will report inconclusive or unsuccessful Phase 3 results in the SAM-002 trial. The high probability of negative or ambiguous outcomes suggests market participants assign meaningful risk to the drug failing to demonstrate efficacy sufficient for regulatory approval. Current market pricing is driven by baseline skepticism about sublingual minoxidil as a novel delivery mechanism for a known compound, though limited recent clinical data appears publicly available. The resolution hinges on when Samson reports Phase 3 trial results, which would definitively establish whether the formulation met its primary efficacy endpoints. This matters because positive results would represent a new treatment option for androgenetic alopecia, while negative results would redirect the company's development priorities.

Key factors:
- Sublingual minoxidil is a reformulation of an existing compound; market may be pricing in difficulty demonstrating meaningful advantage over established topical delivery
- Phase 3 trial design specifics (primary endpoints, patient population, comparator choice) would significantly influence outcome probability if disclosed
- Absence of publicly available interim data or recent company updates may reflect either deliberate information control or lack of compelling preliminary signals
- Timeline to results announcement remains undefined; extended timelines without updates typically correlate with lower success probability in biotech markets
- Competitor landscape and regulatory precedent for other novel hair-loss formulations could shift probability if new approvals or failures occur

Contracts:
- Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report No Results Phase 3 results in SAM-002?: No Results — 71¢ Kalshi $560 (weight 100%)
- Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report Success Phase 3 results in SAM-002?: Success — 16¢ Kalshi $0 (weight 0%)
- Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report Failure Phase 3 results in SAM-002?: Failure — 5¢ Kalshi $0 (weight 0%)
- Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report Mixed Phase 3 results in SAM-002?: Mixed — 3¢ Kalshi $0 (weight 0%)
- Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report Ambiguous Phase 3 results in SAM-002?: Ambiguous — 3¢ Kalshi $0 (weight 0%)

---

## Methodology

SimpleFunctions aggregates live YES-side prices from Kalshi and Polymarket contracts bound to this question. For binary topics the headline is the liquidity-weighted mid-price (weight = log(1 + 24h volume) × freshness, where freshness is 1.0 if updated <24h, 0.7 if <7d, 0.4 otherwise). For multi-outcome (winner-take-all) topics the headline is the current leader's price — disjoint outcomes are never arithmetically averaged. Snapshots refresh every 5 minutes during market hours.

## SF Signal

- SF Index, regime, and 30d Brier calibration are computed separately and surfaced at https://simplefunctions.dev/admin/calibration.
- No SimpleFunctions index / regime / calibration signal is bound to this topic yet — the headline above is market-derived only.

---

*Last verified: 2026-06-26T13:20:51.553Z*

By SimpleFunctions — https://simplefunctions.dev/

Cite as: "71% per prediction markets (SimpleFunctions, June 2026)"
Canonical: https://simplefunctions.dev/answer/samson
Full data: https://simplefunctions.dev/api/public/query?q=Will%20Samson%20Clinical%20Operations's%20male%20Androgenetic%20Alopecia%20(AGA)%20drug%20(Sublingual%20Minoxidil)%20report%20No%20Results%20Phase%203%20results%20in%20SAM-002
Provider: SimpleFunctions — https://simplefunctions.dev